Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
June 2023 in “Frontiers in Genetics” Genes related to calcium signaling and lipid metabolism are important for curly hair in Mangalitza pigs.
Stem cell therapy shows promise for better burn healing but needs more research and standardization.
June 2021 in “International journal of cosmetics and dermatology” Vitamin C and E may help with certain skin and hair conditions, but more research is needed to confirm their effectiveness.
1 citations
,
January 2021
June 2025 in “Current Issues in Molecular Biology” Minoxidil, caffeine, and biotin can improve hair shine by restoring certain genes.
April 2024 in “Journal of translational medicine” Melanocytes are important for normal body functions and have potential uses in regenerative medicine and disease treatment.
32 citations
,
May 2023 in “Frontiers in Immunology” Understanding cellular interactions in VCA may lead to better treatments and reduce rejection.
June 2020 in “Journal of Investigative Dermatology” Red clover extract-based scalp treatments significantly improved hair volume and reduced hair loss and damage.
68 citations
,
December 2010 in “The journal of investigative dermatology/Journal of investigative dermatology” HOXC13 is essential for hair and nail development by regulating Foxn1.
April 2023 in “Journal of Investigative Dermatology” The document's conclusion cannot be provided because the content is not accessible.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
November 2019 in “Journal of Medicinal Food” January 2016 in “Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver” The new biodegradable nanocarriers safely and effectively deliver drugs into the skin.
December 2011 in “Drug Research” The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
AnnoPharma effectively identifies substances causing adverse drug reactions in medical abstracts.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
November 2009 in “Regenerative Medicine” The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.
10 citations
,
May 2016 in “Polymer” New nanocarriers improve skin drug delivery with low toxicity at certain concentrations.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.